Werewolf Therapeutics Debt-to-Equity Ratio Growth & History (HOWL)
Werewolf Therapeutics's debt-to-equity ratio was 1.67 for fiscal 2025.
View full Werewolf Therapeutics company overviewWerewolf Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.67 | 1.09 | +185.17% |
| 2024 | 2024-12-31 | 0.59 | 0.11 | +24.28% |
| 2023 | 2023-12-31 | 0.47 | 0.35 | +293.47% |
| 2022 | 2022-12-31 | 0.12 | 0.02 | +17.10% |
| 2021 | 2021-12-31 | 0.10 | — | — |
Werewolf Therapeutics quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.00 | −1.02 | — |
| Q1 2026 | 2026-03-31 | 3.35 | 2.61 | +351.88% |
| Q4 2025 | 2025-12-31 | 1.67 | 1.09 | +185.17% |
| Q3 2025 | 2025-09-30 | 1.41 | 0.93 | +191.23% |
| Q2 2025 | 2025-06-30 | 1.02 | 0.60 | +142.39% |
| Q1 2025 | 2025-03-31 | 0.74 | 0.30 | +68.22% |
| Q4 2024 | 2024-12-31 | 0.59 | 0.11 | +24.28% |
| Q3 2024 | 2024-09-30 | 0.48 | 0.37 | +319.89% |
| Q2 2024 | 2024-06-30 | 0.42 | 0.30 | +263.51% |
| Q1 2024 | 2024-03-31 | 0.44 | 0.32 | +276.30% |
| Q4 2023 | 2023-12-31 | 0.47 | 0.35 | +293.47% |
| Q3 2023 | 2023-09-30 | 0.12 | −0.00 | −0.49% |
| Q2 2023 | 2023-06-30 | 0.12 | −0.00 | −3.70% |
| Q1 2023 | 2023-03-31 | 0.12 | 0.00 | +3.71% |
| Q4 2022 | 2022-12-31 | 0.12 | 0.02 | +17.10% |
| Q3 2022 | 2022-09-30 | 0.12 | 0.10 | +860.53% |
| Q2 2022 | 2022-06-30 | 0.12 | 0.11 | +882.28% |
| Q1 2022 | 2022-03-31 | 0.11 | — | — |
| Q4 2021 | 2021-12-31 | 0.10 | — | — |
| Q3 2021 | 2021-09-30 | 0.01 | — | — |
| Q2 2021 | 2021-06-30 | 0.01 | — | — |
Werewolf Therapeutics debt-to-equity ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Werewolf Therapeutics's debt-to-equity ratio increased from 0.10 to 1.67, a change of 1.57. The latest reported quarter, Q2 2026, shows 0.00.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Werewolf Therapeutics source filings ↗